Folic acid, single added active ingredient by mouth,
does it really help with Hemoglobin increase in confirmed folate-deficient megaloblastic anemia?
research showsFolic acid is a recognized replacement treatment for folate-deficient megaloblastic anemia. However, this search did not verify a between-group Hb effect for oral folic acid alone versus a folate-free control matching the fixed question in nonpregnant adults with B12 deficiency excluded. ? does not mean treatment is ineffective and is not advice to delay diagnosis or treatment. [S11]
ads claimPregnancy, stroke, mechanisms and folate biomarker changes do not establish this fixed Hb contrast. ? must not be used to claim that replacement treatment is unnecessary.
Four separate assessment dimensions
| Effect direction and size | The question’s between-group Hb change, adjusted final difference, variance, confidence interval, P value, arm-specific analysis denominators, fixed follow-up and clinically important threshold remain unverified. Values were not filled with 0 and no effect size or NNT was reconstructed from biomarkers or uncontrolled recovery. |
|---|---|
| Evidence certainty | The current value is ? with a null score. Only claim type B and laboratory surrogate endpoint S are classified; the five later axes and strength count remain unscored null. Human studies were identified, but a directly eligible between-group result for this fixed question was not verified. This does not mean that human research is absent. |
| Applicability | The question is limited to isolated deficiency. Pregnancy/lactation, pediatric cases, mixed B12/iron deficiency, renal disease, hemolysis, aplasia, and drug-, alcohol-, malabsorption-, inflammation- or cancer-related causes were not pooled. Diagnostic cutoffs, formulation, dose and duration in an eligible trial remain unverified. |
| Safety | Safety is Caution. Folic acid can improve the hematologic manifestations of B12 deficiency and delay recognition of neurologic harm; official labeling warns against treating B12 deficiency or undiagnosed anemia with folic acid alone. Hb recovery does not establish resolution of a B12 problem. Efficacy grading and safety are separate. |
There is no assumption that withholding treatment is acceptable. The supplied RE exception nevertheless requires all five gates to be established. Objective diagnosis, a direct replacement mechanism and prospective human observation are acknowledged. However, the historical absence of placebo trials and quantified untreated mortality/irreversible harm were not established; RE was not applied. The rule allowing prospective observation was not replaced with a requirement for a placebo RCT.
Useful facts when choosing a product
- Official product document S11 describes single-ingredient oral folic acid tablets and the folate-deficient megaloblastic anemia indication. Its adult 5 mg/day for 4 months is a product-label regimen, not a placebo-controlled effect estimate for this question or an individual dosing instruction. [S11]
- The question is limited to isolated deficiency. Pregnancy/lactation, pediatric cases, mixed B12/iron deficiency, renal disease, hemolysis, aplasia, and drug-, alcohol-, malabsorption-, inflammation- or cancer-related causes were not pooled. Diagnostic cutoffs, formulation, dose and duration in an eligible trial remain unverified.
Chamgap Semantic Classification Code
Permanent code issued
M.folic-acid.oral.folate-deficient-megaloblastic-anemia-b12-excluded-hemoglobin.increase.folate-free-same-background-careMedicinal interventions > Folic acid > Oral > Hemoglobin in isolated folate-deficient megaloblastic anemia with B12 deficiency excluded > Increase > Folate-free comparator under the same background care
Scope is fixed to nonpregnant, nonlactating adults with laboratory-confirmed isolated folate-deficient megaloblastic anemia; eligible-comparison formulation, dose, duration and effect remain unverified. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | M · Medicine |
|---|---|
| Canonical ingredient or intervention | Folic acid |
| Source or part used | Sole added active ingredient; manufacturing source, batch and purity not verified in an eligible trial. |
| Formulation or processing | Single-ingredient oral preparation is the question boundary; eligible-trial salt, dosage form and brand unverified. |
| Route | Oral |
| Dose | Unverified: dose and frequency in an eligible comparison. |
| Duration | Unverified: eligible-comparison treatment and follow-up duration. |
| Population | Nonpregnant, nonlactating adults; laboratory-confirmed isolated folate-deficient megaloblastic anemia; B12 deficiency excluded. Separate special etiologies. |
| Effect or condition | Increase in hemoglobin |
| Primary endpoint | Between-group change in blood hemoglobin at a predefined follow-up; appropriately adjusted final difference separately. Separate g/dL, g/L and time points. |
| Comparator | Folate-free placebo/no treatment/usual care under the same background treatment; actual eligible comparison unverified. |
| Duplicate-detection key | M|folic-acid|oral|nonpregnant-adult-lab-confirmed-isolated-folate-deficient-megaloblastic-anemia-B12-excluded|Hb-between-group-increase|folate-free-same-care |
What the research actually shows
Golding is a prospective single-person depletion-and-repletion observation involving 1 participant. Marrow, folate and B12-related tests were reported, but there was no concurrent folate-free control. Diet resumption and folate supplementation changed together, so no isolated between-group Hb increase was calculated. [S01]
In that experiment, normal diet and folate supplementation resumed on study day 586; the Hb, red-cell and hematocrit nadir was near day 588 and return to initial levels was reported by day 772. These are study-day coordinates, not a controlled treatment effect or a general recovery timetable. Hb magnitudes were not digitized from graphs. [S01]
The participant maintained methylcobalamin 1000 µg/day and underwent B12-related monitoring. Investigations relevant to excluding B12 deficiency and concurrent B12 exposure were distinguished. The before-after contrast was not treated as a randomized comparison isolating folic acid. [S01]
The Shammo study enrolled 9 patients receiving olaparib for cancer and contained a small comparison assigning 2 to oral folic acid 1 mg/day and 2 to no supplementation. The original placebo plan changed to no supplementation because of cost. The entire cohort of 9 was not used as the denominator of randomized arm-specific Hb analyses. [S02]
That study primarily assessed the frequency and timing of folate deficiency, with Hb secondary. Cancer/drug-related etiology, incomplete verification of the exact population stratum, and olaparib dose reductions in controls prevent attribution to this isolated-deficiency question. Normalization of folate and the authors’ Hb interpretation were not converted into a formal between-group effect or proof of equivalence. [S02]
In that trial, allocation followed mild anemia with serum folate <7 ng/mL and Hb <12 g/dL; Hb <10 g/dL triggered rescue folate irrespective of allocation. These were that oncology protocol’s criteria, not universal confirmation criteria for folate deficiency or megaloblastic anemia. [S02]
A case involving alcohol, liver disease and bleeding, a tropical-sprue study, pregnancy studies, and B12 plus folic acid in multiple sclerosis were retained as separate etiologies or interventions. Positive hematologic recovery was not transferred into a between-group Hb value for this single-ingredient population. [S03, S04, S07, S13]
Why this is classified as ?
The current value is ? with a null score. Only claim type B and laboratory surrogate endpoint S are classified; the five later axes and strength count remain unscored null. Human studies were identified, but a directly eligible between-group result for this fixed question was not verified. This does not mean that human research is absent.
There is no assumption that withholding treatment is acceptable. The supplied RE exception nevertheless requires all five gates to be established. Objective diagnosis, a direct replacement mechanism and prospective human observation are acknowledged. However, the historical absence of placebo trials and quantified untreated mortality/irreversible harm were not established; RE was not applied. The rule allowing prospective observation was not replaced with a requirement for a placebo RCT. [S01, S02, S11, S12]
Counterpoint. A case involving alcohol, liver disease and bleeding, a tropical-sprue study, pregnancy studies, and B12 plus folic acid in multiple sclerosis were retained as separate etiologies or interventions. Positive hematologic recovery was not transferred into a between-group Hb value for this single-ingredient population. [S03, S04, S07, S13] The Swiss HTA evaluates the clinical utility of folate testing. Its limitations in testing evidence were not converted into ineffectiveness of replacement treatment or a global absence of treatment research. [S12]
Rejudgment record. The question’s between-group Hb change, adjusted final difference, variance, confidence interval, P value, arm-specific analysis denominators, fixed follow-up and clinically important threshold remain unverified. Values were not filled with 0 and no effect size or NNT was reconstructed from biomarkers or uncontrolled recovery. — The current value is ? with a null score. Only claim type B and laboratory surrogate endpoint S are classified; the five later axes and strength count remain unscored null. Human studies were identified, but a directly eligible between-group result for this fixed question was not verified. This does not mean that human research is absent.
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
Stored derived and displayed grades match; this is not a current recalculation or validity check (?).
Review performed and remaining limitations
The question’s between-group Hb change, adjusted final difference, variance, confidence interval, P value, arm-specific analysis denominators, fixed follow-up and clinically important threshold remain unverified. Values were not filled with 0 and no effect size or NNT was reconstructed from biomarkers or uncontrolled recovery.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| FAM-GOLDING-2014 | single-person self-experiment with depletion and repletion | {"participants": 1, "randomized": 0, "eligible_concurrent_control": 0, "analysis_unit": "person; analytical replicates are not participants"} | Study-specific verified and unverified states are in evidence_appraisal.json. | Hb trajectory, folate assays, marrow, MCV; no formal controlled Hb effect | Objective deficiency, marrow findings and Hb recovery are documented, but no isolated folic-acid versus no-folate between-group comparison; diet resumption and cointerventions coexist. | Not used to grade a direct effect; context or exclusion. |
| FAM-OLAPARIB-NCT04024254 | small open-label randomized component embedded in prospective oncology study | {"consented": 10, "enrolled": 9, "randomized_total": 4, "folic_acid": 2, "no_folic_acid": 2, "nonrandomized": 5, "followed_12_months": 5, "denominator_note": "12-month completion refers to the whole cohort, not both randomized arms; no fixed-time Hb arm analysis denominator established."} | Study-specific verified and unverified states are in evidence_appraisal.json. | Primary: folate deficiency frequency/timing. Hb a secondary endpoint, without formal eligible between-group estimate | Cancer/drug-associated deficiency; no verified isolated megaloblastic/B12-excluded stratum with a between-group Hb estimate. Olaparib reduction was asymmetric. | Not used to grade a direct effect; context or exclusion. |
| FAM-CLARKE-2010 | case report | {"participants": 1} | Study-specific verified and unverified states are in evidence_appraisal.json. | Clinical recovery narrative; not a controlled mean Hb contrast | Case with alcohol, liver disease and bleeding; not a controlled Hb effect. | Not used to grade a direct effect; context or exclusion. |
| FAM-SHEEHY-1961 | historical dose-titration study in tropical sprue | {} | Study-specific verified and unverified states are in evidence_appraisal.json. | Hematologic response, not a verified matching Hb contrast | Tropical sprue is a malabsorption population; matched B12 exclusion, oral no-folate control and Hb effect unverified. | Not used to grade a direct effect; context or exclusion. |
| FAM-OBEID-2017 | supplementation trial screened at index level | {} | Study-specific verified and unverified states are in evidence_appraisal.json. | Folate biomarkers | Folate-biomarker supplementation rather than confirmed megaloblastic anemia treatment. | Not used to grade a direct effect; context or exclusion. |
| FAM-NOZARI-2019 | placebo-controlled multicomponent supplementation | {} | Study-specific verified and unverified states are in evidence_appraisal.json. | Anemia/quality measures; isolated folic-acid Hb effect unavailable | Multiple sclerosis and combined B12 plus folic acid addition. | Not used to grade a direct effect; context or exclusion. |
| FAM-LASSI-PREGNANCY-REVIEW | systematic review inherited from 121 | {} | Study-specific verified and unverified states are in evidence_appraisal.json. | Maternal prevention outcomes | Pregnancy studies are not replications of nonpregnant deficiency treatment. | Not used to grade a direct effect; context or exclusion. |
Receipt — 13 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: none
Cite this verdict
[Chamgap] Does oral folic acid raise hemoglobin versus control in folate-deficient megaloblastic anemia? — Evidence Grade ?. 13 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/folic-acid-folate-deficient-megaloblastic-anemia-b12-excluded-hemoglobin/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.